Fundraising Fox
Solid Biosciences
NASDAQ: SLDBCharlestown, US · Delaware corporation · 4 known investors
Find your way into Solid Biosciences
Sign up to find every way you can get introduced to Solid Biosciences
- Your email: who you already know at Solid Biosciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Solid Biosciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy. It also develops genetic regulator libraries and delivery platform technologies intended to improve gene therapy delivery.
Founders & leadership
Board
Investors · 4
How we know: Bain Capital Life Sciences's portfolio page · board seat on SEC Form D · funding news · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · the S-1 prospectus · funding news · Not right? Tell us
How we know: baincapital.com · Not right? Tell us
Funding
SEC filings, press & company announcements$109.2M disclosed across 3 of 5 rounds · 2017–2026
▶$9.2MraisedDec 2022 · 13 investors · PharmaceuticalsRule 506(b)
- Lynne SullivanDirector
- Adam KoppelDirector
- Stephen DiPalmaExecutive Officer
- Martin FreedDirector
- Alexander (Bo) CumboExecutive Officer, Director
- Paul HerizchExecutive Officer
- Clare KahnDirector
- Georgia KerestyDirector
- Adam StoneDirector
- Rajeev ShahDirector
- Robert HuffinesDirector
- Carl MorrisExecutive Officer
- Jessie HanrahanExecutive Officer
- Sukumar NagendranDirector
- Ilan GanotDirector
- David Tyronne HowtonExecutive Officer
- Jennifer MarloweExecutive Officer
- Ian SmithDirector
- Offering amount
- $9.2M
- Amount sold
- $9.2M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40MraisedOct 2020 · 1 investors · PharmaceuticalsRule 506(b)
- Ian SmithDirector
- Martin FreedDirector
- Lynne SullivanDirector
- Adam StoneDirector
- Matthew ArnoldDirector
- Rajeev ShahDirector
- Sukumar NagendranDirector
- Adam KoppelDirector
- Robert HuffinesDirector
- Joel SchneiderExecutive Officer
- Carl MorrisExecutive Officer
- Lynette HerschaExecutive Officer
- Ilan GanotExecutive Officer, Director
- Jennifer ZiolkowskiExecutive Officer
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60MraisedJul 2019 · 15 investors · PharmaceuticalsRule 506(b)
- Carl MorrisExecutive Officer
- Martin FreedDirector
- Lynne SullivanDirector
- Ilan GanotExecutive Officer, Director
- Alvaro AmorrortuExecutive Officer
- Lynette HerschaExecutive Officer
- Andrey ZarurDirector
- Joel SchneiderExecutive Officer
- Jorge A. QuirozExecutive Officer
- Jennifer ZiolkowskiExecutive Officer
- Robert HuffinesDirector
- Adam KoppelDirector
- Sukumar NagendranDirector
- Rajeev ShahDirector
- Matthew ArnoldDirector
- Adam StoneDirector
- Offering amount
- $60M
- Amount sold
- $60M
- Sales commissions
- $1.8M
- Placement agents
- SVB Leerink LLC
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 3
Companies working in the same space as Solid Biosciences.
Frequently asked questions
- What does Solid Biosciences do?
- Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy. It also develops genetic regulator libraries and delivery platform technologies intended to improve gene therapy delivery.
- Who founded Solid Biosciences?
- Solid Biosciences was founded by Ilan Ganot.
- Who are Solid Biosciences's investors?
- Solid Biosciences's investors include Bain Capital Life Sciences, Foresite Capital, RA Capital, Bain Capital.
- How much funding has Solid Biosciences raised?
- Solid Biosciences has disclosed $109.2M raised across 3 of its 5 known rounds.
- Where is Solid Biosciences headquartered?
- Solid Biosciences is headquartered in Charlestown, US.